Journal: The Journal of Cell Biology
Article Title: Insights into retinal disease and non-tubulin glutamylation from a RPGR–TTLL5 complex structure
doi: 10.1083/jcb.202508020
Figure Lengend Snippet: A minimal C-terminal helix in the RPGR BD is sufficient for CID binding and intercalates into the CID helical bundle through a conserved aromatic network. (A) Domain organization of human TTLL5 and RPGR. TTL catalytic core, blue; cMTBD, maroon; CID, green. RCC1-like β-propeller domain in RPGR, yellow, with each repeat shown as a separate propeller blade. Sequence for the minimal BD peptide required for TTLL5 targeting to RPGR shown in magenta at the top. (B) ITC measurements of WT miniBD peptide titrated into CID. Best fit of n = 2 independent experimental replicates. (C) 2.8-Å X-ray crystal structure of human TTLL5 CID in complex with human RPGR miniBD shown in cartoon representation; CID, green; RPGR, magenta. (D and E) Key conserved hydrophobic interactions at the CID–BD interface. Solid black boxes around residue labels designate disease-associated mutations, dashed boxes designate mutations without disease annotation in the ClinVar database that we predict are pathogenic based on our structure. RPGR and TTLL5 are colored as in B; H-bonds are shown as dashed lines.
Article Snippet: Vectors were sequenced by Psomagen standard Sanger sequencing service.
Techniques: Binding Assay, Sequencing, Residue